Skip to main content

Table 4 Effect of cisplatin (CP) and different treatments of AHE on phase II antioxidant enzymes

From: Modulatory influence of Acacia hydaspica R. Parker ethyl acetate extract against cisplatin inveigled hepatic injury and dyslipidemia in rats

Group GSH (μM/g tissue) GR (nM/min/mg protein) GST (nM/min/mg protein) γ-GT (nM/min/mg Protein) GPx (nM/min/mg Protein)
Control 19.61 ± 0.28 b 163.6 ± 0.65 b 142.6 ± 0.57 b 336.2 ± 0.56 b 139.5 ± 1.16 b
CP 10.08 ± 0.28 a 103.9 ± 0.65 a 101.4 ± 0.84 a 143.6 ± 1.44 a 90.53 ± 1.71 a
AHE alone 20.11 ± 0.16 b 164.2 ± 0.68 b 142.7 ± 0.89 b 336.3 ± 1.0 b 139.8 ± 0.36 b
CP + AHE 12.83 ± 0.21a,b d 122.8 ± 0.65a,b,d 122.1 ± 0.87a,b,d 215.3 ± 1.85a,b,d 108.6 ± 1.25 a,b
AHE + CP 18.38 ± 0.29a*,b, c 145.5 ± 0.58a,b,c 135.3 ± 0.77a,b, c 310.4 ± 0.6 a,b,c 128.6 ± 1.74 a,b
CP + Sily 18.34 ± 0.11a*,b 148.7 ± 1.09 a, b 130.0 ± 0.92 a, b 309.5 ± 0.69 a, b 131.8 ± 1.28 a,b
  1. Values expressed as mean ± SEM
  2. a Significance at p < 0.0001 Vs. control group
  3. b Significance at p < 0.0001 Vs. Cisplatin (CP) group
  4. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
  5. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
  6. * Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)